Regeneron Pharmaceuticals (NASDAQ:REGN) Lowered to “Hold” at StockNews.com

StockNews.com cut shares of Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) from a buy rating to a hold rating in a research report released on Thursday.

REGN has been the subject of several other reports. Jefferies Financial Group assumed coverage on Regeneron Pharmaceuticals in a report on Monday, June 6th. They issued an underperform rating and a $536.00 price objective for the company. SVB Leerink assumed coverage on shares of Regeneron Pharmaceuticals in a report on Monday, May 23rd. They issued an outperform rating and a $738.00 target price for the company. Wells Fargo & Company reduced their target price on shares of Regeneron Pharmaceuticals from $750.00 to $735.00 and set an overweight rating for the company in a report on Friday, June 3rd. Cowen boosted their target price on shares of Regeneron Pharmaceuticals from $640.00 to $645.00 in a report on Wednesday, April 20th. Finally, Barclays boosted their target price on shares of Regeneron Pharmaceuticals from $700.00 to $745.00 and gave the stock an overweight rating in a report on Tuesday, April 12th. Two equities research analysts have rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of Buy and an average target price of $711.05.

REGN stock opened at $556.75 on Thursday. The company has a debt-to-equity ratio of 0.14, a current ratio of 4.76 and a quick ratio of 4.09. The business has a 50-day moving average price of $657.02 and a 200 day moving average price of $644.48. The company has a market capitalization of $60.43 billion, a P/E ratio of 7.89, a PEG ratio of 1.76 and a beta of 0.25. Regeneron Pharmaceuticals has a 1-year low of $516.75 and a 1-year high of $747.42.

Regeneron Pharmaceuticals (NASDAQ:REGNGet Rating) last released its quarterly earnings data on Wednesday, May 4th. The biopharmaceutical company reported $11.49 earnings per share for the quarter, beating the consensus estimate of $9.37 by $2.12. The firm had revenue of $2.97 billion during the quarter, compared to the consensus estimate of $2.69 billion. Regeneron Pharmaceuticals had a return on equity of 50.10% and a net margin of 48.06%. The firm’s quarterly revenue was up 17.2% on a year-over-year basis. During the same period in the previous year, the company posted $10.09 earnings per share. On average, analysts anticipate that Regeneron Pharmaceuticals will post 40.63 earnings per share for the current fiscal year.

In related news, Director Bonnie L. Bassler sold 1,240 shares of the company’s stock in a transaction that occurred on Thursday, April 7th. The stock was sold at an average price of $725.00, for a total value of $899,000.00. Following the sale, the director now owns 1,082 shares in the company, valued at $784,450. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Robert E. Landry sold 300 shares of the company’s stock in a transaction that occurred on Monday, March 21st. The stock was sold at an average price of $693.00, for a total value of $207,900.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 29,334 shares of company stock worth $20,660,288. 10.76% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the business. BlackRock Inc. boosted its position in Regeneron Pharmaceuticals by 2.6% in the 4th quarter. BlackRock Inc. now owns 9,610,871 shares of the biopharmaceutical company’s stock worth $6,069,457,000 after purchasing an additional 244,009 shares in the last quarter. Vanguard Group Inc. boosted its position in Regeneron Pharmaceuticals by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 8,360,330 shares of the biopharmaceutical company’s stock worth $5,839,023,000 after purchasing an additional 201,815 shares in the last quarter. Capital World Investors boosted its position in Regeneron Pharmaceuticals by 11.8% in the 1st quarter. Capital World Investors now owns 5,949,834 shares of the biopharmaceutical company’s stock worth $4,155,451,000 after purchasing an additional 626,199 shares in the last quarter. State Street Corp boosted its position in Regeneron Pharmaceuticals by 6.8% in the 1st quarter. State Street Corp now owns 5,125,467 shares of the biopharmaceutical company’s stock worth $3,579,729,000 after purchasing an additional 325,645 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Regeneron Pharmaceuticals by 11.9% in the 4th quarter. JPMorgan Chase & Co. now owns 4,591,529 shares of the biopharmaceutical company’s stock worth $2,899,642,000 after purchasing an additional 489,084 shares in the last quarter. Institutional investors and hedge funds own 83.83% of the company’s stock.

Regeneron Pharmaceuticals Company Profile (Get Rating)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

See Also

Analyst Recommendations for Regeneron Pharmaceuticals (NASDAQ:REGN)

Want More Great Investing Ideas?

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.